Patents Examined by Savitha Rao
  • Anti-viral compounds
    Patent number: 9073946
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: July 7, 2015
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Ernesto J. Muñoz, Myra W. Imanaka, Kerry W. Fowler
  • Methods and compositions for treating inflammatory bowel disease
    Patent number: 9072763
    Abstract: The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: July 7, 2015
    Assignee: RedHill Biopharma Ltd.
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • Use of tylvalosin as antiviral agent
    Patent number: 9066964
    Abstract: The invention relates to the use of a macrolide antibiotic, tylvalosin, as an anti-viral agent. Tylvalosin is particularly useful for the treatment of PRRSV.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: June 30, 2015
    Assignees: Cambridge University Technical Services, Eco Animal Health Limited
    Inventors: Albert Philip Adrian Mockett, Thomas David Kay Brown, Amanda Denise Stuart
  • Substituted pyrimidinone-phenyl-pyrimidinyl compounds
    Patent number: 9056110
    Abstract: The present disclosure provides pyrimidinone-phenyl-pyrimidinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and inflammatory disease, having the structure of Formula (I): wherein R1, R2, R3, R4 and R5 are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: June 16, 2015
    Assignee: CONFLUENCE LIFE SCIENCES, INC.
    Inventors: Shaun R. Selness, Balekudru Devadas, Susan L. Hockerman, Joseph B. Monahan
  • Fatty acid-salicylate conjugates with enhanced therapeutic properties
    Patent number: 9056139
    Abstract: The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: June 16, 2015
    Assignee: KEAN UNIVERSITY
    Inventor: Evros Vassiliou
  • Method for treatment of bone diseases and fractures
    Patent number: 9056105
    Abstract: Described herein are compounds, compositions, and methods useful for treating bone diseases or defects. Also described herein are compounds, compositions and methods for treating bone diseases or defects by inhibiting phosphatase complexes.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: June 16, 2015
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Hiroki Yokota, Ping Zhang
  • Pyrazine derivatives as ENaC blockers
    Patent number: 9050339
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Lee Edwards, Catherine Howsham, Peter Hunt, Nichola Smith
  • Iminosugars and methods of treating viral diseases
    Patent number: 9044470
    Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: June 2, 2015
    Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of The University of Oxford
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • WNT protein signalling inhibitors
    Patent number: 9045416
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: June 2, 2015
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Michael G. Roth, Baozhi Chen, Chuo Chen, Michael E. Dodge, Wei Tang
  • Interaction control of cationic biocides using labile anionic polyelectrolytes
    Patent number: 9040510
    Abstract: Methods of inhibiting the uptake of cationic biocides into medical devices such as contact lenses and implants are described. Methods of stabilizing emulsions containing cationic biocides are also described. In particular, the present invention provides for the use of polymers acting as labile anionic polyelectrolytes to reversibly bind cationic biocides. The reversible binding can reduce the deleterious effects of cationic biocides while maintaining biocidal activity. Preferred polymers include galactomannan and polyvinyl alcohol.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: May 26, 2015
    Assignee: Alcon Research, Ltd.
    Inventors: Howard Allen Ketelson, Ryan Desousa, Nissanke L. Dassanayake, Mary E. Luck
  • Alpha adrenergic receptor modulators
    Patent number: 9040532
    Abstract: Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: May 26, 2015
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Liming Wang, Wenkui K. Fang, Evelyn G. Corpuz, Santosh C. Sinha, Daniel W. Gil, Mohammad I. Dibas, John E. Donello
  • Binding interaction of proanthocyanidins with bacteria and bacterial components
    Patent number: 9040250
    Abstract: A composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6. A method of administering to an immunosuppressed patient or a patient diagnosed with sepsis or septic shock a composition having a proanthocyanidin. A method of administering to a patient diagnosed with a gram negative bacterial infection a composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: May 26, 2015
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: James B Delehanty, Brandy J White, Baochuan Lin, Frances S Ligler
  • Methods and compositions comprising at least one ?3 ?A4 nAChR antagonist or pharmaceutically acceptable salt thereof
    Patent number: 9040591
    Abstract: The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one ?3 ?4 nAChR antagonist and formulations comprising at least one ?3 ?4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: May 26, 2015
    Assignee: AGI Therapeutics Public Limited Company
    Inventor: John Devane
  • Methods for the treatment of senile dementia of the alzheimer's type
    Patent number: 9034923
    Abstract: The present invention relates to the treatment of Senile Dementia of the Alzheimer's Type (SDAT) by administering to the patient and effective amount of 1-alkyl, 2-acyl-glycerol.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: May 19, 2015
    Assignee: Phenomenome Discoveries Inc.
    Inventor: Dayan Burke Goodenowe
  • Pharmaceutical composition containing low-substituted hydroxypropyl cellulose
    Patent number: 9034860
    Abstract: Disclosed is a pharmaceutical composition containing a compound represented by the general formula (I) below or a pharmacologically acceptable salt thereof, while having improved dissolvability. Specifically disclosed is a pharmaceutical composition containing (A) a compound represented by the general formula (I) below or a pharmacologically acceptable salt thereof, and (B) a low-substituted hydroxypropyl cellulose.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 19, 2015
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, UBE INDUSTRIES, LTD.
    Inventors: Tomoyuki Watanabe, Kazuko Maeda
  • Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
    Patent number: 9023893
    Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: May 5, 2015
    Assignee: Novartis AG
    Inventors: William Hewitt, Daniel L Vasella, Randy L Webb
  • Lipase inhibitors for the treatment of pancreatitis and organ failure
    Patent number: 9023887
    Abstract: The present invention relates to methods for treating pancreatitis and/or organ failure comprising administering, to a subject in need of such treatment, an effective amount of a lipase inhibitor. It is based, at least in part, on the discoveries that lipotoxicity contributes to inflammation, multisystem organ failure, necrotic pancreatic acinar cell death and in acute pancreatitis, and that inhibition of lipolysis was able to reduce indices associated with these conditions. Accordingly, in various embodiments, the present invention provides for methods and compositions for limiting lipotoxicity and thereby reducing the likelihood of poor outcomes associated with acute pancreatitis and other severe systemic conditions, especially in obese individuals.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: May 5, 2015
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventor: Vijay Prem Singh
  • Photosensitizing compositions
    Patent number: 9026203
    Abstract: The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 5, 2015
    Assignee: PCI Biotech AS
    Inventors: Jo Klaveness, Anders Hogset
  • Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
    Patent number: 9023894
    Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: May 5, 2015
    Assignee: Novartis AG
    Inventors: William Hewitt, Daniel L Vasella, Randy L Webb
  • Composition and method for treating or preventing skeletal muscle fibrosis
    Patent number: 9023859
    Abstract: A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 5, 2015
    Assignees: State of Israel, Ministry of Agriculture, Agricultural Research Organization, Hadasit Medical Research Services and Development Company
    Inventors: Mark Pines, Arnon Nagler